Aptorum Group Ltd. has announced a collaboration between DiamiR Biosciences and Instant NanoBiosensors $(INB)$ to validate INB’s automated APOE testing platform for Alzheimer’s disease. The partnership aims to introduce an automated testing solution for Alzheimer's disease risk assessment into clinical practice, increasing testing capabilities and laboratory throughput. DiamiR will assess INB's G8 Genotyping Analyzer for APOE testing within its CLIA-certified, CAP-accredited laboratory, comparing it to its current New York State approved APOE test. Financial and other terms of the agreement were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aptorum Group Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9646922-en) on February 02, 2026, and is solely responsible for the information contained therein.